Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response
Authors
Keywords
-
Journal
PHARMACOLOGY & THERAPEUTICS
Volume 236, Issue -, Pages 108108
Publisher
Elsevier BV
Online
2022-01-07
DOI
10.1016/j.pharmthera.2022.108108
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
- (2021) Hope S. Rugo et al. JAMA Oncology
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synergistic Platinum(II) Prodrug Nanoparticles for Enhanced Breast Cancer Therapy
- (2020) Chen-Xi Yang et al. MOLECULAR PHARMACEUTICS
- Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis
- (2020) Qingxin Mu et al. PLoS One
- Advances in liposomal drug delivery to cancer: An overview
- (2020) Shivani Saraf et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Synergistic Chemotherapy for Breast Cancer and Breast Cancer Brain Metastases via Paclitaxel-Loaded Oleanolic Acid Nanoparticles
- (2020) Youmei Bao et al. MOLECULAR PHARMACEUTICS
- Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals
- (2020) Gergely Tibor Kozma et al. ADVANCED DRUG DELIVERY REVIEWS
- Controlled solvent removal from antiviral drugs and excipients in solution enables the formation of novel combination multi-drug-motifs in pharmaceutical powders composed of lopinavir, ritonavir and tenofovir
- (2020) Jesse Yu et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules
- (2020) Jesse Yu et al. PHARMACEUTICAL RESEARCH
- The Therapeutic Efficacy of Dendrimer and Micelle Formulations for Breast Cancer Treatment
- (2020) Sibusiso Alven et al. Pharmaceutics
- Nanomedicines accessible in the market for clinical interventions
- (2020) Vedant Gadekar et al. JOURNAL OF CONTROLLED RELEASE
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
- (2019) Takashi Nakada et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives
- (2019) Braeden Medeiros et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
- (2019) Lawrence D Mayer et al. International Journal of Nanomedicine
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Vivo Evaluation of Dual-Targeted Nanoparticles Encapsulating Paclitaxel and Everolimus
- (2019) Houdaihed et al. Cancers
- Current status of nanomedicine in the chemotherapy of breast cancer
- (2019) A. I. Fraguas-Sánchez et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Patient-Derived Xenograft Models of Breast Cancer and Their Application
- (2019) Murayama et al. Cells
- The role of liposomes in clinical nanomedicine development. What now? Now what?
- (2019) Daan J.A. Crommelin et al. JOURNAL OF CONTROLLED RELEASE
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor targeting via EPR: Strategies to enhance patient responses
- (2018) Susanne K. Golombek et al. ADVANCED DRUG DELIVERY REVIEWS
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)–poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy
- (2018) Shiliang Dong et al. ANTI-CANCER DRUGS
- Breast cancer metastasis through the lympho-vascular system
- (2018) S. David Nathanson et al. CLINICAL & EXPERIMENTAL METASTASIS
- Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects
- (2018) M. Pistelli et al. Current Oncology
- Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook
- (2018) Qingxin Mu et al. JOURNAL OF DRUG TARGETING
- Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection
- (2018) Lisa A. McConnachie et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice
- (2018) Ethel R. Pereira et al. SCIENCE
- Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
- (2018) M. Brown et al. SCIENCE
- Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells
- (2018) Amila K. Nanayakkara et al. Scientific Reports
- Conjugate of PAMAM Dendrimer, Doxorubicin and Monoclonal Antibody—Trastuzumab: The New Approach of a Well-Known Strategy
- (2018) Monika Marcinkowska et al. Polymers
- Extended cell and plasma drug levels after one dose of a 3-in-1 nanosuspension containing lopinavir, efavirenz, and tenofovir in non-human primates
- (2018) Josefin Koehn et al. AIDS
- Three HIV drugs, atazanavir, ritonavir and tenofovir co-formulated in drug-combination nanoparticles exhibit long-acting and lymphocyte targeting properties in non-human primates
- (2018) Simone Perazzolo et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics
- (2018) Thomas Vangijzegem et al. Expert Opinion on Drug Delivery
- Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment
- (2018) Jing Zhang et al. MOLECULES
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy
- (2017) Jingjing Sun et al. JOURNAL OF CONTROLLED RELEASE
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment
- (2017) Maryam Afsharzadeh et al. Artificial Cells Nanomedicine and Biotechnology
- Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
- (2016) J. Baselga et al. CLINICAL CANCER RESEARCH
- Breast Cancer Epidemiology and Risk Factors
- (2016) KRISTIN ROJAS et al. CLINICAL OBSTETRICS AND GYNECOLOGY
- Genetically engineered mouse models in oncology research and cancer medicine
- (2016) Kelly Kersten et al. EMBO Molecular Medicine
- Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
- (2016) Peng Zhang et al. JOURNAL OF CONTROLLED RELEASE
- In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate
- (2016) Liuxi Chen et al. mAbs
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- CA4-loaded doxorubicin prodrug coating Fe3O4 nanoparticles for tumor combination therapy
- (2016) Hongmei Liu et al. RSC Advances
- Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice
- (2015) Huan Meng et al. ACS Nano
- Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure Duration as Well as Triple-Drug Combination Levels in Cells Within Lymph Nodes and Blood in Primates
- (2015) Jennifer P. Freeling et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer
- (2015) Ilkoo Noh et al. BIOMATERIALS
- GEMMs as preclinical models for testing pancreatic cancer therapies
- (2015) Aarthi Gopinathan et al. Disease Models & Mechanisms
- Preclinical studies of dendrimer prodrugs
- (2015) Chie Kojima Expert Opinion on Drug Metabolism & Toxicology
- Chemotherapy for Metastatic Breast Cancer – An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
- (2015) A. Schneeweiss et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
- (2015) Andreas Wicki et al. JOURNAL OF CONTROLLED RELEASE
- Mesoscale Nanoparticles Selectively Target the Renal Proximal Tubule Epithelium
- (2015) Ryan M. Williams et al. NANO LETTERS
- Translational value of mouse models in oncology drug development
- (2015) Stephen E Gould et al. NATURE MEDICINE
- Breast cancer metastasis and the lymphatic system
- (2015) MUNAZZAH RAHMAN et al. Oncology Letters
- Systems Approach to targeted and long-acting HIV/AIDS therapy
- (2015) Rodney J. Y. Ho et al. Drug Delivery and Translational Research
- Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
- (2015) Alexandra Canonici et al. Oncotarget
- Nanomedicine Scale-up Technologies: Feasibilities and Challenges
- (2014) Rishi Paliwal et al. AAPS PHARMSCITECH
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling
- (2014) Darren Michael Moss et al. BRITISH JOURNAL OF PHARMACOLOGY
- Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
- (2014) Sohita Dhillon DRUGS
- Animal models for exploring the pharmacokinetics of breast cancer therapies
- (2014) Omar M Rashid et al. Expert Opinion on Drug Metabolism & Toxicology
- Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway
- (2014) Elvin Blanco et al. MOLECULAR THERAPY
- Advances in the chemistry of dendrimers
- (2014) Marta Sowinska et al. NEW JOURNAL OF CHEMISTRY
- Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer
- (2014) Bo Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New HER2-Positive Targeting Agents in Clinical Practice
- (2014) Sara Tolaney Current Oncology Reports
- Dendrimers: synthesis, applications, and properties
- (2014) Elham Abbasi et al. Nanoscale Research Letters
- Breast cancer as a systemic disease: a view of metastasis
- (2013) A. J. Redig et al. JOURNAL OF INTERNAL MEDICINE
- Trends in Translational Medicine and Drug Targeting and Delivery: New Insights on an Old Concept—Targeted Drug Delivery with Antibody–Drug Conjugates for Cancers
- (2013) J.Y. Rodney et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Emerging Research and Clinical Development Trends of Liposome and Lipid Nanoparticle Drug Delivery Systems
- (2013) John C. Kraft et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Biomarkers of Residual Disease, Disseminated Tumor Cells, and Metastases in the MMTV-PyMT Breast Cancer Model
- (2013) Christian Franci et al. PLoS One
- Quantum dots as a platform for nanoparticle drug delivery vehicle design
- (2012) Christine E. Probst et al. ADVANCED DRUG DELIVERY REVIEWS
- Arginine functionalized peptide dendrimers as potential gene delivery vehicles
- (2012) Kui Luo et al. BIOMATERIALS
- Progesterone Receptor Isoform Functions in Normal Breast Development and Breast Cancer
- (2012) Anastasia Kariagina et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- Metal-organic frameworks as potential drug delivery systems
- (2012) Chun-Yi Sun et al. Expert Opinion on Drug Delivery
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Physiologically Based Pharmacokinetic Model for Composite Nanodevices: Effect of Charge and Size on In Vivo Disposition
- (2012) Donald E. Mager et al. PHARMACEUTICAL RESEARCH
- Biologically Optimized Nanosized Molecules and Particles: More than Just Size
- (2011) Michelle R. Longmire et al. BIOCONJUGATE CHEMISTRY
- Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increasedin vivoactivity
- (2011) Jerzy Gubernator Expert Opinion on Drug Delivery
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative
- (2011) J. P. Thakkar et al. ONCOLOGIST
- Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage
- (2010) Carrie Anna Geisberg et al. CURRENT HYPERTENSION REPORTS
- The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer
- (2010) Donald P McDonnell et al. CURRENT OPINION IN PHARMACOLOGY
- The molecular pathology of breast cancer progression
- (2010) Alessandro Bombonati et al. JOURNAL OF PATHOLOGY
- Combinatorial Drug Conjugation Enables Nanoparticle Dual-Drug Delivery
- (2010) Santosh Aryal et al. Small
- Toxicity of therapeutic nanoparticles
- (2009) Melissa A Maurer-Jones et al. Nanomedicine
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
- (2008) Grazia Arpino et al. ENDOCRINE REVIEWS
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
- (2008) Paul Tardi et al. LEUKEMIA RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started